

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

## **Sihuan Pharmaceutical Holdings Group Ltd.**

四環醫藥控股集團有限公司

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

### **VOLUNTARY ANNOUNCEMENT NOTIFICATION LETTER OF THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION OF XUANZHU BIOPHARM**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that recently, Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”, stock code: 02575.HK), a non wholly-owned subsidiary of the Group, received the official notification letter on its application for H Share Full Circulation (the “**Notification**”) from the CSRC, pursuant to which Xuanzhu Biopharm’s filing with the CSRC regarding the conversion of a total of 357,245,794 Unlisted Shares held by 6 Shareholders into 357,245,794 H Shares on a one-to-one basis has been completed. Upon completion of such conversion and listing approval granted by the Stock Exchange of Hong Kong Limited (“**Stock Exchange**”), such 357,245,794 H Shares will be listed and traded on the Main Board of the Stock Exchange. The Notification shall be valid for 12 months from the date of approval by the CSRC, being March 26, 2026. Please refer to the inside information announcement released by Xuanzhu Biopharm on 12 April, 2026 for details of the names of share holders and number of Unlisted Shares for conversion under the H Share Full Circulation plan of Xuanzhu Biopharm.

As at the date of this announcement, details of Xuanzhu Biopharm’s implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. Xuanzhu Biopharm will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in compliance with the Listing Rules and/or Inside Information Provisions as and when appropriate.

The completion of the H Share Full Circulation and the Conversion and Listing is subject to other relevant procedures as required by the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company and Xuanzhu Biopharm are advised to exercise caution when dealing in the shares of the Company and Xuanzhu Biopharm.

## **ABOUT XUANZHU BIOPHARM**

Xuanzhu Biopharm is an innovative pharmaceutical company rooted in China with a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development (“**R&D**”), production and commercialization of class 1 drugs with core proprietary intellectual property rights. The company has a first-class R&D team that all core personnel have years of experience in new drug R&D. The company has two R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. The dual engines drive the company’s innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first class innovative pharmaceutical company with independent R&D, production, and sales capabilities.

## **ABOUT SIHUAN PHARMACEUTICAL**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 12 April 2026

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*